INTRON A
Biological
Merck Sharp & Dohme Corporation
Total Payments
$1.1M
Transactions
29
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $223,750 | 1 | 0 |
| 2018 | $425,533 | 12 | 0 |
| 2017 | $403,820 | 16 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Neoadjuvant Combination Biotherapy with Pembrolizumab MK-3475 and High Dose IFN- 2b in Patients with Locally,Regionally Advanced,Recurrent Melanoma Safety, Efficacy and Biomarker Study | Merck Sharp & Dohme Corporation | $649,455 | 0 |
| Pilot Analysis of the Effects of IFN a2b upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients with and without Tumor-Involved Sentinel Lymph Nodes | Merck Sharp & Dohme Corporation | $223,750 | 0 |
| Neoadjuvant Combination Biotherapy With Ipilimumab 3 mg,kg Or 10 mg,kg And High Dose IFN- 2b In Patients With Locally,Regionally Advanced,Recurrent Melanoma A Randomized Safety, Efficacy And Biomarker Study | Merck Sharp & Dohme Corporation | $104,794 | 0 |
| Neoadjuvant Combination Biotherapy with Pembrolizumab MK-3475 and High Dose IFN- 2b in Patients with Locally,Regionally Advanced,Recurrent Melanoma# Safety, Efficacy and Biomarker Study | Merck Sharp & Dohme Corporation | $40,704 | 0 |
| Biomarker Analysis of E1690 Identification of Molecular Prognostic and Predictive Factors | Merck Sharp & Dohme Corporation | $34,400 | 0 |
Top Doctors Receiving Payments for INTRON A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $1.1M | 29 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 0
- Transactions 29
About INTRON A
INTRON A is a biological associated with $1.1M in payments to 0 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $223,750 was paid across 1 transactions to 0 doctors.
The most common payment nature for INTRON A is "Unspecified" ($1.1M, 100.0% of total).
INTRON A is associated with 5 research studies, including "Neoadjuvant Combination Biotherapy with Pembrolizumab MK-3475 and High Dose IFN- 2b in Patients with Locally,Regionally Advanced,Recurrent Melanoma Safety, Efficacy and Biomarker Study" ($649,455).